{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:40:51Z","timestamp":1778924451416,"version":"3.51.4"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0233500","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T17:56:57Z","timestamp":1589824617000},"page":"e0233500","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-093X","authenticated-orcid":true,"given":"Armand","family":"Van Deun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-1484","authenticated-orcid":true,"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Kya Jai Maug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Anwar","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-6490","authenticated-orcid":true,"given":"Murid","family":"Gumusboga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimer","family":"Ortu\u00f1o-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutgarde","family":"Lynen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouke C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans L.","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"issue":"suppl 2","key":"pone.0233500.ref001","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"W Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref002","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"A Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref003","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days","volume":"167","author":"A Jindani","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0233500.ref004","first-page":"1","article-title":"WHO Expert Committee on Tuberculosis. Eighth Report","volume":"290","author":"World Health Organization","year":"1964","journal-title":"Tech Rep Ser"},{"key":"pone.0233500.ref005","first-page":"1","article-title":"WHO Expert Committee on Tuberculosis. Ninth Report","volume":"552","author":"World Health Organization","year":"1974","journal-title":"Tech Rep Ser"},{"key":"pone.0233500.ref006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0041-3879(80)90012-4","article-title":"Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African\/British Medical Research Council Study","volume":"61","author":"East African Medical Research Council, British Medical Research Council","year":"1980","journal-title":"Tubercle"},{"key":"pone.0233500.ref007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0041-3879(75)90050-1","article-title":"A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months","volume":"56","author":"Hong Kong Tuberculosis Treatment Services, Brompton Hospital, British Medical Research Council","year":"1975","journal-title":"Tubercle"},{"key":"pone.0233500.ref008","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0140-6736(04)17141-9","article-title":"Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial","volume":"364","author":"A Jindani","year":"2004","journal-title":"Lancet"},{"key":"pone.0233500.ref009","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0007-0971(84)90165-7","article-title":"Final report: results during the 36 months after the end of chemotherapy and beyond","volume":"78","author":"British Thoracic Society. A controlled trial of 6 months\u2019 chemotherapy in pulmonary tuberculosis","year":"1984","journal-title":"Br J Dis Chest"},{"key":"pone.0233500.ref010","unstructured":"World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Third edition. World Health Organization Document. 2003;WHO\/CDS\/TB\/2003.313:1\u2013108."},{"key":"pone.0233500.ref011","first-page":"423","article-title":"Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis","volume":"133","author":"DA Mitchison","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"pone.0233500.ref012","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis","volume":"17","author":"M Gegia","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pone.0233500.ref013","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis","volume":"6","author":"F Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"key":"pone.0233500.ref014","unstructured":"World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization Document. 2018;WHO\/CDS\/TB\/2018.7:1\u201331."},{"key":"pone.0233500.ref015","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(18)30550-4","article-title":"Occult rifampicin-resistant tuberculosis: better assays are needed","volume":"18","author":"E Variava","year":"2018","journal-title":"(Comment). Lancet Infect Dis"},{"key":"pone.0233500.ref016","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.5588\/ijtld.18.0158","article-title":"Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring","volume":"22","author":"A Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref017","article-title":"Double-dose rifampicin throughout first-line tuberculosis treatment is well tolerated, a randomized clinical trial","volume":"24","author":"KJM Aung","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref018","first-page":"756","article-title":"Limitations and requirements for quality control of sputum smear microscopy for acid-fast bacilli","volume":"2","author":"A Van Deun","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref019","first-page":"21","article-title":"Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes","volume":"41","author":"G Canetti","year":"1969","journal-title":"Bull World Health Organ"},{"key":"pone.0233500.ref020","first-page":"143","article-title":"Drug susceptibility of Mycobacterium tuberculosis in a rural area of Bangladesh and its relevance to the national treatment regimens","volume":"3","author":"A Van Deun","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref021","first-page":"23","article-title":"Drug resistance monitoring: combined rates may be the best indicator of programme performance","volume":"8","author":"A Van Deun","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref022","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5588\/ijtld.14.0200","article-title":"Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey","volume":"19","author":"SMM Kamal","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5588\/ijtld.14.0651","article-title":"Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients","volume":"19","author":"A Van Deun","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref024","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1128\/JCM.01489-06","article-title":"Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis","volume":"45","author":"L Rigouts","year":"2007","journal-title":"J Clin Microbiol"},{"key":"pone.0233500.ref025","doi-asserted-by":"crossref","first-page":"812","DOI":"10.5588\/ijtld.11.0637","article-title":"Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007\u20132009","volume":"16","author":"M Gegia","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref026","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00077-13","article-title":"Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes","volume":"57","author":"MNT Huyen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0233500.ref027","first-page":"509","article-title":"A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis","volume":"1","author":"Tuberculosis Research Centre Chennai","year":"1997","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref028","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-3156.2004.01229.x","article-title":"Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis\u2014a unique approach","volume":"9","author":"Tuberculosis Research Centre Chennai","year":"2004","journal-title":"Trop Med Int Health"},{"key":"pone.0233500.ref029","doi-asserted-by":"crossref","first-page":"e76189","DOI":"10.1371\/journal.pone.0076189","article-title":"The impact of isoniazid resistance in the treatment outcomes of smear positive re-treatment tuberculosis patients in the State of Andhra Pradesh, India","volume":"8","author":"D Deepa","year":"2013","journal-title":"PLoS One"},{"key":"pone.0233500.ref030","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/thx.2010.148585","article-title":"Treatment of tuberculosis and optimal dosing schedules","volume":"66","author":"KC Chang","year":"2011","journal-title":"Thorax"},{"key":"pone.0233500.ref031","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1164\/rccm.200605-637OC","article-title":"Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis","volume":"174","author":"KC Chang","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0233500.ref032","first-page":"31","article-title":"Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes","volume":"8","author":"T Yoshiyama","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref033","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1086\/425005","article-title":"The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis","volume":"39","author":"KJ Seung","year":"2004","journal-title":"Clin Infect Dis"},{"key":"pone.0233500.ref034","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1001\/jama.283.19.2537","article-title":"Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries","volume":"283","author":"MA Espinal","year":"2000","journal-title":"JAMA"},{"key":"pone.0233500.ref035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JPT Higgins","year":"2003","journal-title":"BMJ"},{"key":"pone.0233500.ref036","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JCM.02741-12","article-title":"Rifampin resistance missed in automated liquid culture systems for Mycobacterium tuberculosis isolates with specific rpoB mutations","volume":"51","author":"L Rigouts","year":"2013","journal-title":"J Clin Microbiol"},{"key":"pone.0233500.ref037","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JCM.00553-13","article-title":"Rifampin drug resistance tests for tuberculosis: challenging the gold standard","volume":"51","author":"A Van Deun","year":"2013","journal-title":"J Clin Microbiol"},{"key":"pone.0233500.ref038","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1128\/JCM.02499-08","article-title":"Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis","volume":"47","author":"WL Huang","year":"2009","journal-title":"J Clin Microbiol"},{"key":"pone.0233500.ref039","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa0907847","article-title":"Rapid molecular detection of tuberculosis and rifampin resistance","volume":"363","author":"CC Boehme","year":"2010","journal-title":"N Engl J Med"},{"key":"pone.0233500.ref040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tube.2013.10.001","article-title":"High degree of multi-drug resistance and heteroresistance in pulmonary TB patients from Punjab state of India","volume":"94","author":"P Kumar","year":"2014","journal-title":"Tuberculosis"},{"key":"pone.0233500.ref041","first-page":"501","article-title":"Detection of multi-drug resistance & characterization of mutations in Mycobacterium tuberculosis isolates from North-Eastern States of India using MTBDRplus assay","volume":"140","author":"R Singhal","year":"2014","journal-title":"Indian J Med Res"},{"key":"pone.0233500.ref042","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1128\/JCM.01602-13","article-title":"Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods","volume":"51","author":"DB Folkvardsen","year":"2013","journal-title":"J Clin Microbiol"},{"key":"pone.0233500.ref043","doi-asserted-by":"crossref","first-page":"e00812","DOI":"10.1128\/mBio.00812-17","article-title":"The new Xpert MTB\/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of care testing","volume":"8","author":"S Chakravorty","year":"2017","journal-title":"mBio"},{"key":"pone.0233500.ref044","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1126\/science.1124410","article-title":"The competitive cost of antibiotic resistance in Mycobacterium tuberculosis","volume":"312","author":"S Gagneux","year":"2006","journal-title":"Science"},{"key":"pone.0233500.ref045","first-page":"952","article-title":"Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for six months","volume":"6","author":"CM Nolan","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref046","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2169\/internalmedicine.9571-17","article-title":"Successful treatment with a high-dose rifampin-containing regimen for pulmonary tuberculosis with a disputed rpoB mutation","volume":"57","author":"DH Jeong","year":"2018","journal-title":"Intern Med (Japan)"},{"key":"pone.0233500.ref047","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"MJ Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pone.0233500.ref048","first-page":"e00717","article-title":"How well do routine molecular diagnostics detect rifampin heteroresistence in Mycobacterium tuberculosis?","volume":"57","author":"KCS Ng","year":"2019","journal-title":"J Clin Microbiol"},{"key":"pone.0233500.ref049","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.5588\/ijtld.12.0407-2","article-title":"Can LED fluorescence microscopy replace Ziehl-Neelsen microscopy in tuberculosis detection?","volume":"16","author":"A Van Deun","year":"2012","journal-title":"In reply. (Correspondence). Int J Tuberc Lung Dis"},{"key":"pone.0233500.ref050","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S1473-3099(18)30496-1","article-title":"Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study","volume":"18","author":"NA Makhado","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"pone.0233500.ref051","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199806043382301","article-title":"Global surveillance for antituberculosis-drug resistance, 1994\u20131997","volume":"338","author":"A Pablos-M\u00e9ndez","year":"1998","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T17:57:14Z","timestamp":1589824634000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233500"}},"subtitle":[],"editor":[{"given":"HASNAIN SEYED","family":"EHTESHAM","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0233500","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,18]]}}}